However, several studies have found that a combination therapy with ACTH plus tacrolimus or CTX is well tolerated by patients with treatment resistant MGN, FSGS, and IgA nephropathy, and that this combination therapy significantly reduces proteinuria and improves clinical response rates compared with ACTH alone (13, 14). This evidence concerns the gene POMC and idiopathic membranous glomerulonephritis.